- Home
- SFL vs GLUE Comparison
SFL vs GLUE Comparison
Compare SFL & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SFL | GLUE |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2004 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SFL | GLUE |
|---|---|---|
| Price | $11.24 | $23.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $12.00 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 1.7M | 1.7M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.05% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $123,672,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.07 | $2.45 |
| P/E Ratio | ★ N/A | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $6.73 | $4.12 |
| 52 Week High | $12.94 | $25.77 |
Technical Indicators
Market Signals| Indicator | SFL | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 54.44 | 59.57 |
| Support Level | $10.89 | $17.35 |
| Resistance Level | $11.52 | $25.45 |
| Average True Range (ATR) | 0.28 | 1.63 |
| MACD | 0.08 | -0.08 |
| Stochastic Oscillator | 87.64 | 69.03 |
Price Performance
Historical ComparisonAbout SFL SFL Corporation Ltd
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities. The company operates as a single reportable segment, generating revenue from long-term, fixed-rate charters. Its Additional revenue sources include sales-type lease interest income, voyage charter and pool revenues, and drilling contract revenues.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).